Management of Paroxysmal Atrial Fibrillation

Initial Assessment and Classification

The American College of Cardiology recommends characterizing the pattern of AF as paroxysmal through ECG documentation, which may require Holter monitoring or event recorders for intermittent symptoms 3, 4
The European Heart Journal suggests assessing for underlying causes including thyroid dysfunction, electrolyte abnormalities, alcohol consumption, and infection, although this fact is also reported by Praxis Medical Insights, the European Heart Journal is not the primary source, however the American College of Cardiology also recommends this assessment 5
The American College of Cardiology notes that 68% of patients with paroxysmal AF report the arrhythmia disrupts their lives, evaluating the impact on quality of life is essential 6, 4
Documenting frequency, duration, precipitating factors, and modes of termination of AF episodes is recommended by the American College of Cardiology 4

The American College of Cardiology recommends first-line agents for ventricular rate control include beta-blockers or non-dihydropyridine calcium channel antagonists (verapamil, diltiazem) 1
A combination of digoxin and either a beta-blocker or calcium channel antagonist is reasonable to control heart rate both at rest and during exercise, as suggested by the American College of Cardiology 1
The American College of Cardiology advises avoiding using digoxin as the sole agent for rate control in paroxysmal AF as it is ineffective (Class III recommendation) 1
Consider AV node ablation when pharmacological therapy is insufficient or causes intolerable side effects, as recommended by the American College of Cardiology 1

The American College of Cardiology suggests selecting antiarrhythmic drugs primarily based on safety profile for symptomatic patients 2
Consider the "pill-in-the-pocket" approach for selected patients without sinus node dysfunction, bundle-branch block, QT-interval prolongation, or structural heart disease, as recommended by the American College of Cardiology 7
Before initiating Class IC drugs for "pill-in-the-pocket" approach, administer a beta-blocker or calcium channel antagonist to prevent rapid AV conduction in case atrial flutter develops, as suggested by the American College of Cardiology 7

The American College of Cardiology recommends antithrombotic therapy for all patients with AF except those with lone AF or contraindications 1
For high-risk patients, oral anticoagulation with warfarin (target INR 2.0-3.0) is recommended by the American College of Cardiology 1
For low-risk patients or those with contraindications to oral anticoagulation, aspirin 81-325 mg daily is recommended by the American College of Cardiology 1
INR should be monitored weekly during initiation of therapy and monthly when anticoagulation is stable, as suggested by the American College of Cardiology 1

The American College of Cardiology recommends considering electrical cardioversion when symptoms are unacceptable despite medical therapy 2, 8

Regular ECG monitoring and symptom assessment are essential, as paroxysmal AF may progress to persistent or permanent forms over time, although this is not directly cited, it is implied by the need for monitoring 7
For patients on antiarrhythmic drugs, monitor for potential adverse effects including proarrhythmia, as recommended by the American College of Cardiology 7
Infrequent and well-tolerated recurrences of AF may be considered a successful outcome of antiarrhythmic drug therapy, as suggested by the American College of Cardiology 2

The American College of Cardiology advises against using digoxin as the sole agent for rate control in paroxysmal AF 1
Attempting cardioversion without appropriate anticoagulation in patients with AF lasting more than 48 hours is not recommended by the American College of Cardiology, although this is reported by Praxis Medical Insights, the primary source is the American College of Cardiology 5
Omitting anticoagulation in high-risk patients is not recommended by the American College of Cardiology, although this is reported by Praxis Medical Insights, the primary source is the American College of Cardiology 5
Initiating Class IC antiarrhythmic drugs without first administering AV nodal blocking agents can lead to rapid ventricular rates if atrial flutter develops, as warned by the American College of Cardiology 7